Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer

BACKGROUND: As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value of whole blood RNA to detect candidate biomarkers in mHSPC remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwan, Edmond M., Fettke, Heidi, Crumbaker, Megan, Docanto, Maria M., To, Sarah Q., Bukczynska, Patricia, Mant, Andrew, Ng, Nicole, Foroughi, Siavash, Graham, Lisa-Jane K., Haynes, Anne-Maree, Azer, Sarah, Lim, Lisi Elizabeth, Segelov, Eva, Mahon, Kate, Davis, Ian D., Parente, Phillip, Pezaro, Carmel, Todenhöfer, Tilman, Sathianathen, Niranjan, Hauser, Christine, Horvath, Lisa G., Joshua, Anthony M., Azad, Arun A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100842/
https://www.ncbi.nlm.nih.gov/pubmed/33968657
http://dx.doi.org/10.21037/tau-20-1444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100842/
https://www.ncbi.nlm.nih.gov/pubmed/33968657
http://dx.doi.org/10.21037/tau-20-1444

Ejemplares similares